|1.||Kojima, Soichi: 1 article (11/2010)|
|2.||Yoneyama, Misao: 1 article (11/2010)|
|3.||Yoshida, Minoru: 1 article (11/2010)|
|4.||Komi, Yusuke: 1 article (11/2010)|
|5.||Ishigami, Ken: 1 article (11/2010)|
|6.||Furumai, Ryohei: 1 article (11/2010)|
|7.||Uchida, Kazuyo: 1 article (11/2010)|
|8.||Watanabe, Hidenori: 1 article (11/2010)|
|9.||Czaicki, Nancy L: 1 article (03/2007)|
|10.||Albert, Brian J: 1 article (03/2007)|
12/01/1996 - "FR901464 exhibited most prominent effects on these tumor systems among the three FR compounds. "
11/01/2010 - "These results suggest that the global interference of gene expression including VEGF in tumor cells is at least one of the mechanisms by which SSA (or FR901464) exhibits its strong antitumor activity."
12/01/1996 - "To address the involvement of transcriptional activation ability of the three FR compounds in the antitumor effect, we selected FR901464 as a candidate compound and investigated cell cycle transition, chromatin status and endogenous gene expression in FR901464-treated tumor cells having elevated transcriptional activity. "
12/01/1996 - "FR901464 also inhibited the growth of murine solid tumors, Colon 38 carcinoma and Meth A fibrosarcoma. "
12/01/1996 - "These results suggest that FR901464 may induce a dynamic change of chromatin structure, giving rise to strong antitumor activity, and therefore may represent a new type of drug for cancer chemotherapy."
12/01/1996 - "The three FR compounds prolonged the life of mice bearing murine ascitic tumor P388 leukemia (T/C values were 160%, 145% and 127% for FR901463, FR901464 and FR901465, respectively), and inhibited the growth of a human solid tumor, A549 lung adenocarcinoma, with different effective dose ranges. "
|5.||Breast Neoplasms (Breast Cancer)
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|2.||DNA (Deoxyribonucleic Acid)
|5.||Adenocarcinoma of lung
|1.||Drug Therapy (Chemotherapy)